pdf   xlsx method abbreviations

mNSCLC - L2 - PDL1 positive, atezolizumab alone , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.77 [0.64, 0.92]< 10%1 study (1/-)99.8 %NAnot evaluable crucial-
progression or deaths (PFS) 0.87 [0.74, 1.03]< 10%1 study (1/-)94.9 %NAnot evaluable important-
DOR 9.61 [3.07, 30.08]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
objective responses (ORR) 1.41 [0.93, 2.14]> 10%1 study (1/-)94.7 %NAnot evaluable non important-

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.